Mounjaro will come in a four-dose device known as a KwikPen for people with type 2 diabetes or obesity
A new weight loss injection will be available in the UK within weeks to treat thousands of patients with type 2 diabetes or obesity, after the medicines watchdog became the first major regulator in the world to greenlight the drug in a more convenient device.
Mounjaro was developed by the US pharmaceutical company Eli Lilly. Trials show it helps those on the highest dose lose more than three stone on average. It is injected under the skin of a patient’s stomach area, thigh or upper arm, and is to be used together with a reduced-calorie diet and increased physical activity.
